David Lok Hang Chan

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Stephen John Clarke · 4 shared papers, 2015–2025 · strength 0.55
   • Paper Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. DOI 10.1111/eci.14341↗
   • Paper The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and… DOI 10.3390/jcm12051989↗
   • Paper Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of … DOI 10.1016/j.ejso.2021.04.005↗
2. Jaswinder Singh Samra · 4 shared papers, 2015–2025 · strength 0.55
   • Paper Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. DOI 10.1111/eci.14341↗
   • Paper The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and… DOI 10.3390/jcm12051989↗
   • Paper Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of … DOI 10.1016/j.ejso.2021.04.005↗
3. Nick Pavlakis · 4 shared papers, 2015–2025 · strength 0.55
   • Paper Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. DOI 10.1111/eci.14341↗
   • Paper The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and… DOI 10.3390/jcm12051989↗
   • Paper Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of … DOI 10.1016/j.ejso.2021.04.005↗
4. Anthony James Gill · 4 shared papers, 2015–2025 · strength 0.55
   • Paper Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. DOI 10.1111/eci.14341↗
   • Paper The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and… DOI 10.3390/jcm12051989↗
   • Paper Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of … DOI 10.1016/j.ejso.2021.04.005↗
5. Sarah Maloney · 3 shared papers, 2021–2025 · strength 0.50
   • Paper Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. DOI 10.1111/eci.14341↗
   • Paper The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and… DOI 10.3390/jcm12051989↗
   • Paper Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of … DOI 10.1016/j.ejso.2021.04.005↗
6. Anubhav Mittal · 3 shared papers, 2021–2025 · strength 0.50
   • Paper Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. DOI 10.1111/eci.14341↗
   • Paper The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and… DOI 10.3390/jcm12051989↗
   • Paper Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of … DOI 10.1016/j.ejso.2021.04.005↗
7. Sumit Sahni · 2 shared papers, 2023–2025 · strength 0.39
   • Paper Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. DOI 10.1111/eci.14341↗
   • Paper The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and… DOI 10.3390/jcm12051989↗
8. Sooin Byeon · 1 shared paper, 2025 · strength 0.23
   • Paper Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. DOI 10.1111/eci.14341↗
9. Angela S. Y. Chou · 1 shared paper, 2025 · strength 0.23
   • Paper Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. DOI 10.1111/eci.14341↗
10. Josef Gillson · 1 shared paper, 2025 · strength 0.23
    • Paper Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. DOI 10.1111/eci.14341↗
11. Malinda Itchins · 1 shared paper, 2023 · strength 0.16
    • Paper The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and… DOI 10.3390/jcm12051989↗
12. Emily K. Colvin · 1 shared paper, 2023 · strength 0.16
    • Paper The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and… DOI 10.3390/jcm12051989↗
13. Terence C. Chua · 1 shared paper, 2021 · strength 0.11
    • Paper Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of … DOI 10.1016/j.ejso.2021.04.005↗
14. Nigel Balfour Jamieson · 1 shared paper, 2021 · strength 0.11
    • Paper Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of … DOI 10.1016/j.ejso.2021.04.005↗
15. Christopher Bahdah Nahm · 1 shared paper, 2021 · strength 0.11
    • Paper Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of … DOI 10.1016/j.ejso.2021.04.005↗
16. Asanka Rohan Wijetunga · 1 shared paper, 2021 · strength 0.11
    • Paper Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of … DOI 10.1016/j.ejso.2021.04.005↗
17. George Hruby · 1 shared paper, 2021 · strength 0.11
    • Paper Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of … DOI 10.1016/j.ejso.2021.04.005↗
18. Lorraine A. Chantrill · 1 shared paper, 2015 · strength 0.05
    • Paper Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report. DOI 10.3892/mco.2015.533↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.